Scott R. Floyd, MD, PhD
Radiation Oncologist
My Locations
About Me
Above all, I value relationships with family and friends. I have seen the devastation that brain tumors cause to ruin these vital relationships. Therefore, I strive to eradicate brain tumors with the best patient care I can and hard work in the laboratory. It is my hope that we will effectively fight brain tumors and preserve relationships.
- Gary Hock and Lyn Proctor Associate Professor of Radiation Oncology, Radiation Oncology 2019
- Associate Professor of Radiation Oncology, Radiation Oncology 2018
- Assistant Research Professor in Pharmacology and Cancer Biology, Pharmacology & Cancer Biology 2016
Call for an Appointment
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
Clinical Focus and Research
I am interested in understanding the causes of primary and metastatic brain tumors and finding more effective therapies to fight these damaging diseases. I participate in clinical trials through the Preston Robert Tisch Brain Tumor Center at Duke and through the Departments of Radiation Oncology and Neurosurgery at the Duke University School of Medicine. I also lead a basic science research laboratory to study brain tumors and identify and test new therapies.
- NEUROD1 function in SCLC fate and plasticity awarded by National Institutes of Health 2024 - 2029
- ASPET SURF Institutional Award awarded by American Society for Pharmacology and Experimental Therapeutics 2018 - 2028
- Synthetic lethality with BET bromodomain inhibition awarded by American Cancer Society, Inc. 2025 - 2026
- Zhao, Jingtong, Eugene Vaios, Zhenyu Yang, Ke Lu, Scott Floyd, Deshan Yang, Hangjie Ji, et al. “Radiogenomic explainable AI with neural ordinary differential equation for identifying post‐SRS brain metastasis radionecrosis.” Medical Physics 52, no. 4 (April 2025): 2661–74. https://doi.org/10.1002/mp.17635.
- Vaios, Eugene J., Rachel F. Shenker, Peter G. Hendrickson, Zihan Wan, Donna Niedzwiecki, David Carpenter, Warren Floyd, et al. “Symptomatic Necrosis With Dual Immune-Checkpoint Inhibition and Radiosurgery for Brain Metastases.” JAMA Netw Open 8, no. 4 (April 1, 2025): e254347. https://doi.org/10.1001/jamanetworkopen.2025.4347.
- Zhao, Jingtong, Eugene Vaios, Yuqi Wang, Zhenyu Yang, Yunfeng Cui, Zachary J. Reitman, Kyle J. Lafata, et al. “Dose-Incorporated Deep Ensemble Learning for Improving Brain Metastasis Stereotactic Radiosurgery Outcome Prediction.” Int J Radiat Oncol Biol Phys 120, no. 2 (October 1, 2024): 603–13. https://doi.org/10.1016/j.ijrobp.2024.04.006.
- Torok, J. A., S. R. Floyd, P. E. Fecci, and J. P. Kirkpatrick. “Hypofractionated Stereotactic Radiosurgery (HF-SRS) in the Treatment of Brain Metastases.” In Central Nervous System Metastases: Diagnosis and Treatment, 329–41, 2020. https://doi.org/10.1007/978-3-030-42958-4_23.
- Zhao, Jingtong, Eugene Vaios, Zhenyu Yang, Ke Lu, Scott Floyd, Deshan Yang, Hangjie Ji, et al. “Radiogenomic explainable AI with neural ordinary differential equation for identifying post-SRS brain metastasis radionecrosis.” In Med Phys, 52:2661–74, 2025. https://doi.org/10.1002/mp.17635.
- Noteware, Laura, Gloria Broadwater, Nicole Dalal, Laura Alder, James E. Herndon Ii, Scott Floyd, William Giles, Amanda E. D. Van Swearingen, Carey K. Anders, and Sarah Sammons. “Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.” In Breast Cancer Res Treat, 197:425–34, 2023. https://doi.org/10.1007/s10549-022-06799-7.
- Huang, Christina C., Jamiluddin Qazi, Jim Leng, David James Carpenter, Brahma Darshni Natarajan, Muzamil Arshad, Olivia Schultz, et al. “Pretreatment clinical parameters associated with intracranial progression burden following an initial stereotactic radiosurgery course in a multi-institutional brain metastases cohort.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- Roundtable Research